114 related articles for article (PubMed ID: 12685841)
1. Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma.
Navarro JT; Ribera JM; Oriol A; Romeu J; Sirera G; Mate JL; Batlle M; Xicoy B; Grau J; Millá F; Feliu E
Leuk Lymphoma; 2002 Sep; 43(9):1837-42. PubMed ID: 12685841
[TBL] [Abstract][Full Text] [Related]
2. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Flores A; Millá F; Feliu E
Br J Haematol; 2001 Mar; 112(4):909-15. PubMed ID: 11298585
[TBL] [Abstract][Full Text] [Related]
3. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Gómez J; Millá F; Feliu E
Haematologica; 1998 Jun; 83(6):508-13. PubMed ID: 9676023
[TBL] [Abstract][Full Text] [Related]
4. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
5. Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
Djunic I; Jevtovic DL; Ranin J; Salemovic D; Tomin D; Mihaljevic B
Biomed Pharmacother; 2008 Jan; 62(1):12-5. PubMed ID: 17629445
[TBL] [Abstract][Full Text] [Related]
6. Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy.
Navarro JT; Ribera JM; Oriol A; Xicoy B; Mate JL; Sirera G; Lloveras N; Millá F; Feliu E
Int J Hematol; 2007 Nov; 86(4):337-42. PubMed ID: 18055341
[TBL] [Abstract][Full Text] [Related]
7. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.
Mounier N; Spina M; Gabarre J; Raphael M; Rizzardini G; Golfier JB; Vaccher E; Carbone A; Coiffier B; Chichino G; Bosly A; Tirelli U; Gisselbrecht C
Blood; 2006 May; 107(10):3832-40. PubMed ID: 16410446
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.
Miralles P; Berenguer J; Ribera JM; Rubio R; Mahillo B; Téllez MJ; Lacruz J; Valencia E; Santos J; Rodríguez-Arrondo F; Pintado V;
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):167-73. PubMed ID: 17117144
[TBL] [Abstract][Full Text] [Related]
10. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy.
Antinori A; Cingolani A; Alba L; Ammassari A; Serraino D; Ciancio BC; Palmieri F; De Luca A; Larocca LM; Ruco L; Ippolito G; Cauda R
AIDS; 2001 Aug; 15(12):1483-91. PubMed ID: 11504980
[TBL] [Abstract][Full Text] [Related]
11. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).
Wolf T; Brodt HR; Fichtlscherer S; Mantzsch K; Hoelzer D; Helm EB; Mitrou PS; Chow KU
Leuk Lymphoma; 2005 Feb; 46(2):207-15. PubMed ID: 15621803
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
Crosswell HE; Bergsagel DJ; Yost R; Lew G
Pediatr Blood Cancer; 2008 Apr; 50(4):883-5. PubMed ID: 17278123
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.
Lim ST; Karim R; Tulpule A; Nathwani BN; Levine AM
J Clin Oncol; 2005 Nov; 23(33):8477-82. PubMed ID: 16230675
[TBL] [Abstract][Full Text] [Related]
14. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors analysis for R-CHOP regimen therapy in diffuse large B cell lymphoma].
Shen Y; Yao Y; Li JM; Chen QS; You JH; Zhao HJ; Chen S; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):252-7. PubMed ID: 18843980
[TBL] [Abstract][Full Text] [Related]
16. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).
Sparano JA; Lee S; Chen MG; Nazeer T; Einzig A; Ambinder RF; Henry DH; Manalo J; Li T; Von Roenn JH
J Clin Oncol; 2004 Apr; 22(8):1491-500. PubMed ID: 15084622
[TBL] [Abstract][Full Text] [Related]
18. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
Toffoli G; Corona G; Cattarossi G; Boiocchi M; Di Gennaro G; Tirelli U; Vaccher E
Ann Oncol; 2004 Dec; 15(12):1805-9. PubMed ID: 15550586
[TBL] [Abstract][Full Text] [Related]
19. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
Navarro JT; Lloveras N; Ribera JM; Oriol A; Mate JL; Feliu E
Haematologica; 2005 May; 90(5):704-6. PubMed ID: 15921395
[TBL] [Abstract][Full Text] [Related]
20. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]